Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation.
Jiménez
O
O
Laboratory of Pharmacology, CBD, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
Campistol
J M
JM
Vidal
E
E
Faura
A
A
Oppenheimer
F
F
Corbella
J
J
Brunet
M
M
D000328:Adult; D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D020123:Sirolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015996:Survival Rate; D016559:Tacrolimus / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013997:Time Factors
D007166:Immunosuppressive Agents; D003404:Creatinine; D020123:Sirolimus; D016559:Tacrolimus